Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema

Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema

An interview with:

Amparo Garcia-Tejedor MD, PhD, Professor of Gynecology, University of Barcelona, Bellvitge University Hospital, Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain.

BARCELONA, Spain—Early results from the ADARNAT study have found that using axillary radiotherapy after neoadjuvant therapy and surgery for women with sentinel node positive early breast cancer was as effective removing lymph nodes while bringing a lower risk of lymphedema.  These preliminary finding were reported at the 2026 European Breast Cancer Conference by Amparo Garcia-Tejedor MD, PhD, Professor of Gynecology at the University of Barcelona’s Bellvitge Hospital, in Barcelona, Spain. Afterwards she gave more details to our reporter, Peter Goodwin:

AUDIO JOURNAL OF ONCOLOGY: Amparo Garcia-Tejedor MD, PhD

IN:  [GOODWIN]”Peter Goodwin here in…..

OUT:  …..of Oncology, I’m Peter Goodwin 6:36secs

EBCC Abstract 7:

Axillary radiotherapy as an alternative to axillary dissection for node-positive breast cancer after neoadjuvant therapy: two-year survival results from the ADARNAT pilot phase

Garcia-Tejedor1, M. Laplana2, S. Salinas3, A. Luzardo3, M. Campos1, C. Ortega1,
Martinez4, M.J. Pla1, A. Guma5, J.G. Reyes-Junca6, S. Pernas7, C. Falo7, J. Azcarate8, J. Ponce1, Spanish ADARNAT Group

1Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain

2Hospital Clínic de Barcelona, Oncological Radiotherapy, Barcelona, Spain

3Hospital Universitari de Bellvitge, Rehabilitation, Hospitalet de Llobregat, Spain

4Institut Català d’Oncología, Oncological Radiotherapy, Hospitalet de Llobregat, Spain

5Hospital Universitari de Bellvitge, Radiology, Hospitalet de Llobregat, Spain

6Hospital Universitari de Bellvitge, Nuclear Medicine, Hospitalet de Llobregat, Spain

7Institut Català d’Oncologia, Medical Oncology, Hospitalet de Llobregat, Spain

8Hospital Universitari de Bellvitge, Pathology, Hospitalet de Llobregat, Spain

Background:

After neoadjuvant therapy (NAT), the optimal management of sentinel lymph node (SLN)-positive axilla remains controversial. Current guidelines still recommend axillary lymphadenectomy (ALND), although evidence increasingly supports less invasive approaches. The ADARNAT trial investigates whether axillary radiotherapy (ART) without lymphadenectomy can safely replace ALND in patients with limited nodal disease after NAT.

Methods:

ADARNAT is an open-label, randomized, phase III multicenter trial across 23 Spanish hospitals. Eligible patients had cT1–T4b, cN0–cN1 breast cancer treated with NAT (chemotherapy or endocrine therapy) and 1–2 positive SLNs (micro- or macrometastases) at surgery. Participants were randomized to ART (experimental arm) or ALND (control arm). Both arms received regional radiotherapy to level III axilla and supraclavicular and/or internal mammary nodes, plus breast/chest wall irradiation when indicated. This report summarizes pilot phase outcomes assessing feasibility and short-term safety.

Results:

From June 2021 to April 2023, 272 patients were enrolled; 102 completed per protocol (46 ART, 56 ALND) with a median follow-up of 2 years. Baseline and pathological characteristics were balanced between arms (Table). No axillary recurrences occurred in the ART arm and one in the ALND arm (1.8%, p=0.3). Distant metastases occurred in 4.4% vs 5.5% (p=0.8), and two deaths were reported in the ALND group (4.3%, p=0.2). Lymphedema was more frequent after ALND (26.7%) than ART (18.9%) without statistical significance (p=0.4). Two-year disease-free and overall survival rates were comparable, supporting the feasibility and short-term oncologic safety of ART.

Conclusions:

The ADARNAT pilot phase suggests that axillary radiotherapy may achieve similar short-term oncologic outcomes to axillary lymphadenectomy in SLN-positive breast cancer after NAT, with comparable toxicity and a trend toward reduced morbidity. These preliminary results support the continuation of the phase III trial to confirm long-term non- inferiority and potential quality-of-life benefits of omitting axillary surgery.

2026 EBCC PRESS RELEASE:

Radiotherapy rather than surgery may help reduce risk of lymphoedema in patients with breast cancer: results from pilot study

Barcelona, Spain: Patients with breast cancer may be able to avoid lymphoedema, which can occur after surgery to remove lymph nodes in the armpit (the axilla), by having radiotherapy instead.

New findings, presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona today (Thursday), suggest that axillary radiotherapy may be as effective at killing any remaining cancer cells, while being less likely to trigger lymphoedema – an often painful swelling of the arm and armpit.

These results come from the pilot phase of a phase III randomised international clinical trial [1, 2] that is investigating whether axillary radiotherapy (ART) has a lower risk of lymphoedema than axillary lymph node dissection (ALND) in patients with breast cancer who have received neoadjuvant systemic therapy, such as chemotherapy or hormone therapy, before surgery, and in whom cancer has spread to only one or two lymph nodes. The trial will also be looking at overall survival and disease-free survival.

The researchers stress that these are preliminary results from two years of follow-up in the pilot study, and that clinicians should wait for the results from the phase III part of the trial, which is ongoing, before considering changing clinical practice.

Professor Amparo Garcia-Tejedor, from the Functional Breast Unit at Bellvitge University Hospital, Spain, and the Institut Català d’Oncologia, is leading the trial. She told the conference that studies had already shown that ART was a good alternative to ALND in patients for whom the first line of treatment was surgery.

“In situations where patients have received chemotherapy or hormone therapy before surgery, it is expected that results could be similar,” she said. “However, robust prospective data are not yet fully established or published.

“Many patients treated with neoadjuvant therapy experience a significant reduction in axillary disease burden and ultimately present with only one or two lymph nodes that are positive for cancer metastases, which often correspond to the sentinel lymph node, while the remaining axillary nodes are negative. This observation strongly suggested that further axillary surgery might be unnecessary in a substantial proportion of patients and that a strategy of de-escalation should be explored.”

From June 2021 to April 2023, the ADARNAT trial (ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer) recruited 272 patients with breast cancer, which might have spread (metastasised) to one or more lymph nodes. The patients had received neoadjuvant therapy and, at the time of surgery, had metastatic cancer in one or two sentinel lymph nodes (the lymph nodes where cancer typically metastasises first). The patients were randomised to receive either ART or ALND; patients in both arms of the trial also received radiotherapy to areas of the breast and chest. Results were available for 46 patients in the ART group and 56 patients in the ALND group, with a median follow-up period of two years.

No cancer recurred in the axillary area in the ART group and one recurred in the ALND group (1.8%). Cancer metastasised to other parts of the body in 4.4% versus 5.5% of the patients, respectively, and there were two deaths in the ALND group (4.3%). Lymphoedema occurred more frequently after ALND (26.7%) than ART (18.9%), although this was not statistically significant. Disease-free and overall survival rates were similar after two years of follow-up.

Prof. Garcia-Tejedor said: “These results indicate that ART instead of ALND is feasible and has good cancer outcomes at two years.

“While some specialists have already begun to substitute axillary lymph node dissection with axillary radiotherapy without waiting for definitive results, the only way to determine with certainty whether this strategy is truly safe and effective is through participation in a well-designed clinical trial such as the one we are now conducting. This is particularly important given that the study population includes patients with residual axillary disease and, therefore, a potentially worse prognosis.

“In this context, treatment decisions should not be made without robust evidence. Our trial is designed to provide the necessary data to definitively answer this question and to ensure that any future change in standard practice is safe in terms of cancer outcomes and is also beneficial for patients.”

Dr Maria Laplana-Torres is a radiation oncologist at the Hospital Clínic de Barcelona, Spain. She presented results from the pilot phase of the trial that showed that although ART was associated with more damage to the skin from radiation, this tended to be transient and easily treatable.

Acute skin damage (grade 2 or above) occurred in 27.8% of ART patients compared with 13.3% after ALND. It consisted mainly of skin redness, pigment changes or skin peeling in some cases. There were no significant differences in later skin damage between the two groups.

She said: “Some patients experienced mild, temporary difficulty raising the arm above the shoulder or lifting it to the side. These limitations were usually short-lived and did not affect everyday activities.

“We found that treating the axilla with radiotherapy instead of extensive surgery can avoid a more aggressive operation without compromising treatment safety in patients with sentinel lymph node involvement. One and two years after treatment, there were no meaningful differences in arm mobility or quality of life between the two groups, although there was a more favourable trend in the ART patients. These results show that axillary radiotherapy may be a safe and less invasive option for some women treated with chemotherapy or hormone therapy before surgery.

“This kind of research is essential to continue improving patient outcomes and to define safer, equally effective therapeutic approaches.”

So far, more than 500 patients have joined the main, phase III clinical trial. The researchers estimate that approximately three more years will be required to complete patient recruitment. This will then be followed by the planned five years of follow-up to fully assess cancer outcomes.

Prof. Garcia-Tejedor concluded: “If the study confirms the safety and effectiveness of axillary treatment de-escalation, the implications for both patients and clinicians could be substantial. For patients, the main potential benefit would be an improvement in quality of life, particularly through a reduction in lymphoedema and other functional complications associated with axillary surgery. For clinicians, these findings would support a paradigm shift in axillary management, reinforcing the move away from routine extensive surgery toward more personalised and less morbid treatment strategies, while maintaining good cancer outcomes.

The Chair of EBCC15, Professor Isabel Rubio, Head of Breast Surgical Oncology at the Clínica Universidad de Navarra in Madrid, Spain, was not involved in this research. She commented: “These findings from the pilot phase of the phase III ADARNAT clinical trial are encouraging. They provide a sound basis for the clinical trial to proceed. Once the trial reports its final results in a few years’ time, we will know whether radiotherapy rather than surgery is safe for patients who have received neoadjuvant treatments.

“While this trial suggests a promising trend towards lower lymphoedema rates with radiation therapy, the next important step is to determine in which patients it may be safe to omit radiation altogether in order to further individualise breast cancer care. Surgical treatment for breast cancer has already moved towards de-escalation, with many patients now able to avoid full axillary lymph node dissection and its associated side effects. However, despite these advances, a significant number of patients still face an increased risk of lymphoedema after radiation therapy. Future research should focus on identifying the subgroup of patients who may not benefit from either axillary dissection or radiation therapy, thereby helping to minimise treatment-related complications while maintaining excellent cancer outcomes.”

260413 Amparo Garcia-Tejedor, 2026 EBCC A J Oncology TEXT